Table 4

Adjusted* relationship between selected risk factors for elevated liver enzyme tests among patients with psoriatic arthritis†

CovariateOR (95% CI)
MTX (mg/week)
    None1.0 (referent)
    2.5–7.51.23 (0.25 to 5.9)
    10–12.53.04 (0.70 to 13.29)
     ⩾152.37 (0.81 to 6.92)
Anti-TNF use (referent to no use)0.82 (0.31 to 2.17)
Body mass index
    <251.0 (referent)
    25–302.97 (0.77 to 11.41)
    >303.09 (0.84 to 11.45)
Current tobacco use1.35 (0.40 to 4.55)
History of liver disorder4.96 (0.95 to 25.90)
Number of liver enzyme test blood draws‡1.22 (0.53 to 2.84)
Alcohol use
    None/occasional1.0 (referent)
    1–3/week1.22 (0.46 to 3.24)
    ⩾1/day2.18 (0.52 to 9.15)
  • *Similar to table 3, additional covariates adjusted for included age, gender, duration of disease, number of physician visits, non-steroidal anti-inflammatory drug use, recent hospitalisation, an interaction term between PsA and alcohol, and folate supplementation.

  • †Defined as alanine aminotransferase or aspartate aminotransferase greater than the upper limit of the laboratory normal.

  • ‡During observation period.

  • OR, odds ratio; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TNF, tumour necrosis factor.